|
|
 |
|
Viewing report
|
|
|
|
Current Treatments, Unmet Needs, and Opportunities in Treating Pediatric Crohn’s Disease
Decision Resources, Inc, Nov 2011
Crohn’s disease (CD) is a relapsing/remitting inflammatory disease of the gastrointestinal (GI) tract. Many of the conventional treatments available for treating children with CD have serious side effects. Interviewed experts indicate substantial unmet needs in current treatment. With only one approved therapy for children—Janssen Biotech/Merck’s Remicade (infliximab)—this market presents a reasonable opportunity for drug developers.
Questions Answered:
- Pediatric CD is a rare disorder. What is the total diagnosed prevalent population for pediatric CD? What is the estimated growth rate of the diagnosed prevalent population by age in the 2010-2020 time period? What age-group will exhibit the maximum growth rate per year in our 2010-2020 study period?
- Remicade is the only approved therapy for pediatric CD patients. What is experts’ opinion of Remicade? Are physicians satisfied with this agent? When do physicians prescribe this agent?
- Interviewed experts indicate that new therapies for pediatric CD is a high unmet need. Are there enough therapies available to treat pediatric CD? What are the drawbacks of the current therapies? What other areas of unmet need do interviewed experts identify? In the opinion of the interviewed experts, how crucial are these unmet needs?
Scope:
- Markets covered: United States.
- Primary research: Four interviews with thought leaders who are pediatric gastroenterologists in the United States and work closely with CD patients.
- Disease Overview: Etiology, pathophysiology, and symptoms and diagnosis of pediatric CD.
- Epidemiology: Diagnosed prevalence of pediatric CD in 2011; estimated diagnosed prevalence by age-group in the 2010-2020 time period.
- Current treatments: Major therapies used to treat pediatric CD.
- Unmet needs: Key considerations for drug developers.
|
|
|
|
